^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    thiotepa

    i
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor, Alkylating agent
    Related drugs:
    5d
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=35, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Mar 2027 --> Sep 2027 | Trial primary completion date: Mar 2025 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    8d
    Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)
    16d
    Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients (clinicaltrials.gov)
    P2, N=23, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Inokai (orelabrutinib) • thiotepa
    19d
    A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Stanford University
    New P1 trial
    |
    fludarabine IV • thiotepa • busulfan • OrcaGraft (engineered donor allograft cell therapy)
    1m
    Allo HSCT for High Risk Hemoglobinopathies (clinicaltrials.gov)
    P2, N=62, Recruiting, Masonic Cancer Center, University of Minnesota
    New P2 trial
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • fludarabine IV • mesna • thiotepa • busulfan
    1m
    Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, Peking University People's Hospital
    New P2 trial
    |
    fludarabine IV • thiotepa • busulfan
    1m
    Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (clinicaltrials.gov)
    P2, N=135, Completed, Fred Hutchinson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
    1m
    Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=35, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • thiotepa
    2ms
    BMT CTN 1507: Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507) (clinicaltrials.gov)
    P2, N=95, Completed, Medical College of Wisconsin | Active, not recruiting --> Completed | Trial primary completion date: Sep 2024 --> Jan 2025
    Trial completion • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • fludarabine IV • hydroxyurea • mesna • thiotepa
    2ms
    US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (clinicaltrials.gov)
    P1/2, N=12, Recruiting, ExCellThera inc. | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • dorocubicel (UM171 cell therapy)
    2ms
    Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL (clinicaltrials.gov)
    P=N/A, N=44, Recruiting, Zhejiang Cancer Hospital
    New trial
    |
    Rituxan (rituximab) • temozolomide • thiotepa
    2ms
    Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    cyclophosphamide • fludarabine IV • thiotepa
    3ms
    CNS-PHLAT: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (clinicaltrials.gov)
    P2, N=36, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD34 (CD34 molecule)
    |
    carmustine • melphalan • thiotepa
    3ms
    Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma (clinicaltrials.gov)
    P3, N=60, Completed, Children's Oncology Group | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Dec 2024
    Trial completion • Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa • Neupogen (filgrastim)
    3ms
    Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule) • CD4 (CD4 Molecule)
    |
    Chr t(15;17)
    |
    cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)
    5ms
    CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Oct 2031 --> Mar 2032 | Trial primary completion date: Oct 2031 --> Mar 2032
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    5ms
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=35, Recruiting, Fred Hutchinson Cancer Center | N=20 --> 35 | Trial completion date: Oct 2026 --> Mar 2027 | Trial primary completion date: Dec 2024 --> Mar 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    5ms
    CNS-PHLAT: CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Washington University School of Medicine
    New P2 trial
    |
    CD34 (CD34 molecule)
    |
    carmustine • melphalan • thiotepa
    5ms
    A multicenter randomized controlled study of intrathecal injection of thiotepa in the treatment of meningeal metastases in non-small cell lung cancer (ChiCTR2400090650)
    P=N/A, N=54, Not yet recruiting, Huashan Hospital, Fudan University; Huashan Hospital, Fudan University
    New trial
    |
    thiotepa
    5ms
    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Initiation date: Sep 2024 --> May 2024
    Trial initiation date
    |
    melphalan • fludarabine IV • thiotepa • Orca-T
    5ms
    Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency: Primary outcomes from the randomized phase III OLIGO study. (PubMed, Eur J Cancer)
    The entire study population experienced long-term survival, with median OS well over five years. IACT compared to CDCT did not improve outcome in patients with OMBC harboring study-defined HRD. The optimal therapy for patients with OMBC requires further study.
    P3 data • Journal • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • HRD (Homologous Recombination Deficiency)
    |
    HR positive • HER-2 negative • HRD
    |
    carboplatin • cyclophosphamide • thiotepa
    6ms
    Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma (clinicaltrials.gov)
    P3, N=60, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa • Neupogen (filgrastim)
    6ms
    NCI-2018-03732: Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025
    Trial completion date
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    MYCN amplification • IL6 expression
    |
    cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane
    6ms
    High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Brukinsa (zanubrutinib) • thiotepa • methotrexate IV
    6ms
    NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jun 2026 --> Oct 2026
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)
    6ms
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (clinicaltrials.gov)
    P2, N=170, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting | N=52 --> 170
    Enrollment closed • Enrollment change
    |
    Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    6ms
    High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma (clinicaltrials.gov)
    P2, N=17, Terminated, Seoul National University Hospital
    New P2 trial
    |
    cyclophosphamide • thiotepa • busulfan
    7ms
    Long-term outcome of the Milano-HART strategy for high-risk medulloblastoma, including the impact of molecular subtype. (PubMed, Neuro Oncol)
    This strategy, partly adopted in the ongoing SIOPE protocol,confirmed improved EFS and OS over previously reported outcomes in all high-risk categories;SHH tumors appeared the most aggressive.
    Journal
    |
    TP53 (Tumor protein P53) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    TP53 mutation • MYCN amplification
    |
    carboplatin • cyclophosphamide • etoposide IV • methotrexate • thiotepa • methotrexate IV
    7ms
    Thiotepa, fludarabine plus busulfan regimen as conditioning regimen prior to allo-HSCT for adult acute lymphoblastic leukemia:a prospective,single-arm, phase 2 study (ChiCTR2400088533)
    P2, N=80, Not yet recruiting, The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University
    New P2 trial
    |
    fludarabine IV • thiotepa • busulfan
    8ms
    Reduced Intensity Transplantation for Severe Sickle Cell Disease (clinicaltrials.gov)
    P2, N=40, Suspended, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Aug 2027 | Trial primary completion date: Jul 2024 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • sirolimus • hydroxyurea • thiotepa • plerixafor
    8ms
    Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Methotrexate in Breast Cancer With Leptomeningeal Metastasis (clinicaltrials.gov)
    P2, N=22, Recruiting, The First Affiliated Hospital with Nanjing Medical University
    New P2 trial • Combination therapy
    |
    thiotepa
    8ms
    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation (clinicaltrials.gov)
    P2, N=52, Recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2025
    Trial completion date • Trial primary completion date
    |
    Rituxan (rituximab) • cyclophosphamide • Blincyto (blinatumomab) • sirolimus • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    8ms
    Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    etoposide IV • melphalan • fludarabine IV • thiotepa • cyclosporin A microemulsion
    8ms
    Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (clinicaltrials.gov)
    P2, N=54, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Oct 2025 --> Oct 2032 | Trial primary completion date: Oct 2024 --> Oct 2031
    Trial completion date • Trial primary completion date
    |
    KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
    |
    cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
    9ms
    New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement (clinicaltrials.gov)
    P2, N=76, Completed, International Extranodal Lymphoma Study Group (IELSG) | Active, not recruiting --> Completed | Trial completion date: Dec 2023 --> Mar 2024
    Trial completion • Trial completion date
    |
    carboplatin • Rituxan (rituximab) • ifosfamide • etoposide IV • carmustine • thiotepa
    9ms
    CY-MET-RIC: Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (clinicaltrials.gov)
    P2, N=82, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Post-transplantation
    |
    cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan
    9ms
    Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cytarabine • fludarabine IV • thiotepa • busulfan
    9ms
    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma (clinicaltrials.gov)
    P2, N=12, Recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2024 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    carboplatin • cyclophosphamide • etoposide IV • melphalan • thiotepa
    9ms
    NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors. (PubMed, Acta Neuropathol Commun)
    Four patients received adjuvant TRK inhibitor therapy (larotrectinib, repotrectinib, or entrectinib), among which three also received chemotherapy (n = 2) or proton therapy (n = 1). This patient had previously experienced relapse after the initial surgery and underwent autologous peripheral blood stem cell therapy with carboplatin/thiotepa and proton therapy. Conclusions Our study clarifies the distinct differences in the pathology and TRK inhibitor response between LGG and HGG with NTRK fusions.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • MDM4 (The mouse double minute 4) • TPM3 (Tropomyosin 3) • TFG (Trafficking From ER To Golgi Regulator) • FKBP15 (FKBP Prolyl Isomerase 15) • KANK1 (KN Motif And Ankyrin Repeat Domains 1) • NTRK (Neurotrophic receptor tyrosine kinase) • SPECC1L (Sperm Antigen With Calponin Homology And Coiled-Coil Domains 1 Like) • GKAP1 (G Kinase Anchoring Protein 1) • KIF5A (Kinesin Family Member 5A)
    |
    carboplatin • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • Augtyro (repotrectinib) • thiotepa
    9ms
    A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies (clinicaltrials.gov)
    P2, N=3, Terminated, St. Jude Children's Research Hospital | N=32 --> 3 | Trial completion date: Apr 2027 --> May 2024 | Recruiting --> Terminated | Trial primary completion date: Apr 2026 --> May 2024; Principal Investigator left institution
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • mesna • thiotepa • busulfan • cyclosporine
    9ms
    TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma (clinicaltrials.gov)
    P2, N=50, Completed, Sheba Medical Center | Active, not recruiting --> Completed | Trial completion date: Apr 2024 --> Jun 2024 | Trial primary completion date: Apr 2024 --> Jun 2024
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cytarabine • etoposide IV • melphalan • thiotepa
    9ms
    CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)
    P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Jun 2031 --> Oct 2031 | Trial primary completion date: Jun 2031 --> Oct 2031
    Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan